ReviewBMC pharmacology & toxicology2018
Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature.
Review in BMC pharmacology & toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Drug-induced hemolytic anemia due to ceftriaxone in a patient with recently identified alloantibodies: A diagnostic challenge.Transfusion · 2026Article
- Ceftriaxone-Induced Immune Hemolytic Anemia and Subsequent Disseminated Intravascular Coagulation.Cureus · 2026Article
- Article
- Case Report: Diagnosis and detection of amoxicillin-induced immune hemolytic anemia.Frontiers in immunology · 2026Article
- Suspected Sildenafil-Induced Immune Hemolytic Anemia Precipitating Acute Kidney Injury Requiring Hemodialysis.Cureus · 2025Article
- Red blood cell agglutination caused by ceftriaxone and its effect on erythrocyte parameters: a case report.Biochemia medica · 2025Article
- Drug-Induced Immune Hemolytic Anemia Following Dapagliflozin Administration: A Case Report.Cureus · 2025Article
- A hyper-acute immune hemolytic anemia induced by contrast medium was successfully treated with eculizumab: a case report.Frontiers in immunology · 2025Article
- Article
- Ceftriaxone-induced severe hemolytic anemia, renal calculi, and cholecystolithiasis in a 3-year-old child: a case report and literature review.Frontiers in pharmacology · 2024Article
- Ceftriaxone-induced hemolytic anemia managed successfully in a 54-year-old woman: a case report and literature review.Frontiers in pharmacology · 2024Article
- Case report: Decreased hemoglobin and multiple organ failure caused by ceftizoxime-induced immune hemolytic anemia in a Chinese patient with malignant rectal cancer.Frontiers in immunology · 2024Article
- Nephrotoxicity of Amoxicillin and Third-Generation Cephalosporins: An Updated Review.Drug safety · 2023Review
- Vancomycin-Induced Hemolytic Anemia.Cureus · 2023Article
- Ceftriaxone-Associated Severe Acute Hepatitis.Cureus · 2023Article
- Clinical-Pathological Conference Series from the Medical University of Graz : Case No 125: A 42-year-old man with loss of appetite, vomiting and stabbing abdominal pain.Wiener klinische Wochenschrift · 2022Article
- Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage.International journal of molecular sciences · 2022Article
- Anti-Anemic Effect of Antioxidant-Rich Apple Vinegar against Phenylhydrazine-Induced Hemolytic Anemia in Rats.Life (Basel, Switzerland) · 2022Article
- Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage?Microorganisms · 2021Review
- Contrast Media-Induced Immune Hemolytic Anemia.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug induced immune hemolytic anemia (DIIHA) is a rare complication and often underdiagnosed. DIIHA is frequently associated with a bad outcome, including organ failure and even death. For the last decades, ceftriaxone has been one of the most common drugs causing DIIHA, and ceftriaxone-induced immune hemolytic anemia (IHA) has especially been reported to cause severe complications and fatal outcomes. CASE PRESENTATION: A 76-year-old male patient was treated with ceftriaxone for cholangitis. Short time after antibiotic exposure the patient was referred to intensive care unit due to cardiopulmonary instability. Hemolysis was observed on laboratory testing and the patient developed severe renal failure with a need for hemodialysis for 2 weeks. Medical history revealed that the patient had been previously exposed to ceftriaxone less than 3 weeks before with subsequent hemolytic reaction. Further causes for hemolytic anemia were excluded and drug-induced immune hemolytic (DIIHA) anemia to ceftriaxone could be confirmed.
conclusionsThe case demonstrates the severity of ceftriaxone-induced immune hemolytic anemia, a rare, but immediately life-threatening condition of a frequently used antibiotic in clinical practice. Early and correct diagnosis of DIIHA is crucial, as immediate withdrawal of the causative drug is essential for the patient prognosis. Thus, awareness for this complication must be raised among treating physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.